Future research should prioritize the development of therapeutic strategies, such as CD2 agonists, to restore CD58 expression in hematological tumors or to circumvent the CD2-CD58 axis to target CD58- immuno-resistant cancer cells. Here, CD58 is linked to hematopoietic and lymphoid system neoplasm.